Cocrystal Pharma Inc
NASDAQ:COCP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cocrystal Pharma Inc
Net Change in Cash
Cocrystal Pharma Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
Net Change in Cash
-$2.8m
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Change in Cash
-$4.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Change in Cash
-$129m
|
CAGR 3-Years
70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
27%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Change in Cash
$91m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Change in Cash
$1.4B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Change in Cash
$4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Cocrystal Pharma Inc
Glance View
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 13 full-time employees. The company went IPO on 2018-03-12. The firm focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The firm focuses on treating influenza virus, coronavirus, hepatitis C virus (HCV) and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The firm uses computational methods to screen and design product candidates using cocrystal structural information. Its development pipeline includes CC-31244 and CC-42344. The Company’s CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. Its pipeline also includes CDI-45205 for the treatment of coronavirus. The company has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.
See Also
What is Cocrystal Pharma Inc's Net Change in Cash?
Net Change in Cash
-2.8m
USD
Based on the financial report for Dec 31, 2025, Cocrystal Pharma Inc's Net Change in Cash amounts to -2.8m USD.
What is Cocrystal Pharma Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
49%
Over the last year, the Net Change in Cash growth was 83%. The average annual Net Change in Cash growth rates for Cocrystal Pharma Inc have been 49% over the past three years .
